These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37954645)

  • 1. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of Tremor Dominant and Postural Instability Gait Difficulty Subtypes During the Progression of Parkinson's Disease: Analysis of the PPMI Cohort.
    Lee JW; Song YS; Kim H; Ku BD; Lee WW
    Front Neurol; 2019; 10():471. PubMed ID: 31133973
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease.
    Chung SJ; Lee PH; Sohn YH; Kim YJ
    J Parkinsons Dis; 2021; 11(4):1715-1724. PubMed ID: 34459414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glucocerebrosidase mutations and uric acid levels in Parkinson's disease: A 3-years investigation of a potential biomarker".
    Mozafar M; Kazemian S; Hoseini E; Mohammadi M; Alimoghadam R; Shafie M; Mayeli M;
    Clin Park Relat Disord; 2023; 8():100177. PubMed ID: 36590455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.
    Stebbins GT; Goetz CG; Burn DJ; Jankovic J; Khoo TK; Tilley BC
    Mov Disord; 2013 May; 28(5):668-70. PubMed ID: 23408503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-phase
    Kim MS; Park DG; An YS; Yoon JH
    Eur J Neurol; 2023 Feb; 30(2):344-352. PubMed ID: 36288409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
    Simuni T; Caspell-Garcia C; Coffey C; Lasch S; Tanner C; Marek K;
    Parkinsonism Relat Disord; 2016 Jul; 28():62-7. PubMed ID: 27132498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia.
    Jeong EH; Sunwoo MK; Song YS
    Front Neurol; 2018; 9():1133. PubMed ID: 30619078
    [No Abstract]   [Full Text] [Related]  

  • 12. Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson's disease.
    Nabizadeh F; Sodeifian F; Pirahesh K
    Neurol Sci; 2022 Aug; 43(8):4745-4752. PubMed ID: 35508569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrastriatal
    Nicastro N; Garibotto V; Burkhard PR
    BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
    Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
    Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels.
    Adams C; Suescun J; Haque A; Block K; Chandra S; Ellmore TM; Schiess MC
    Clin Park Relat Disord; 2023; 8():100187. PubMed ID: 36793590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution pattern of iron deposition in the basal ganglia of different motor subtypes of Parkinson's disease.
    Zhang X; Li L; Qi L; Fu Y; Sun D; Chen S; Xu W; Liu C; Zhou X; He G
    Neurosci Lett; 2023 Jun; 807():137249. PubMed ID: 37061026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
    Sun X; Dou K; Xue L; Xie Y; Yang Y; Xie A
    Clin Transl Sci; 2024 Jan; 17(1):e13720. PubMed ID: 38266062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of MDS-UPDRS Motor Subtypes Over Three Years in Early Parkinson's Disease.
    Kohat AK; Ng SYE; Wong ASY; Chia NSY; Choi X; Heng DL; Li W; Ng HL; Chua ST; Neo SXM; Xu Z; Tay KY; Au WL; Tan EK; Tan LCS
    Front Neurol; 2021; 12():704906. PubMed ID: 34630281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.